{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:32:11Z","timestamp":1790069531453,"version":"4.0.1"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81872897"],"award-info":[{"award-number":["81872897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81402943"],"award-info":[{"award-number":["81402943"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81672966,"],"award-info":[{"award-number":["81672966,"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Major Collaborative Innovation Project","award":["2016-I2M-1-011"],"award-info":[{"award-number":["2016-I2M-1-011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0725-7","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T11:02:57Z","timestamp":1568199777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy"],"prefix":"10.1136","volume":"7","author":[{"given":"Jing","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9060-3988","authenticated-orcid":false,"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiying","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"725_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/1744666X.2017.1366315","volume":"13","author":"H Yousefi","year":"2017","unstructured":"Yousefi H, Yuan J, Keshavarz-Fathi M, Murphy JF, Rezaei N. Immunotherapy of cancers comes of age. Expert Rev Clin Immunol. 2017;13:1001\u201315.","journal-title":"Expert Rev Clin Immunol"},{"key":"725_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24\u201333.","journal-title":"Trends Mol Med"},{"key":"725_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41:868\u201376.","journal-title":"Cancer Treat Rev"},{"key":"725_CR4","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116.","journal-title":"Sci Transl Med"},{"key":"725_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1756-8722-6-74","volume":"6","author":"L Shi","year":"2013","unstructured":"Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74.","journal-title":"J Hematol Oncol"},{"key":"725_CR6","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.2174\/1381612823666171004120152","volume":"23","author":"Q Geng","year":"2018","unstructured":"Geng Q, Jiao P, Jin P, Su G, Dong J, Yan B. PD-1\/PD-L1 inhibitors for Immuno-oncology: from antibodies to small molecules. Curr Pharm Des. 2018;23:6033\u201341.","journal-title":"Curr Pharm Des"},{"key":"725_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/jnci\/82.1.54","volume":"82","author":"EC Kohn","year":"1990","unstructured":"Kohn EC, Liotta LA. L651582: a novel antiproliferative and antimetastasis agent. J Natl Cancer Inst. 1990;82:54\u201360.","journal-title":"J Natl Cancer Inst"},{"key":"725_CR8","first-page":"569","volume":"56","author":"EC Kohn","year":"1996","unstructured":"Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. 1996;56:569\u201373.","journal-title":"Cancer Res"},{"key":"725_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0169-5002(02)00525-1","volume":"39","author":"TW Moody","year":"2003","unstructured":"Moody TW, Chiles J, Moody E, Sieczkiewicz GJ, Kohn EC. CAI inhibits the growth of small cell lung cancer cells. Lung Cancer (Amsterdam, Netherlands). 2003;39:279\u201388.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"725_CR10","first-page":"935","volume":"54","author":"EC Kohn","year":"1994","unstructured":"Kohn EC, Felder CC, Jacobs W, Holmes KA, Day A, Freer R, et al. Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res. 1994;54:935\u201342.","journal-title":"Cancer Res"},{"key":"725_CR11","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1200\/JCO.1997.15.5.1985","volume":"15","author":"EC Kohn","year":"1997","unstructured":"Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, et al. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol. 1997;15:1985\u201393.","journal-title":"J Clin Oncol"},{"key":"725_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.lungcan.2007.10.003","volume":"60","author":"EA Johnson","year":"2008","unstructured":"Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, et al. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97\u201324-51). Lung Cancer (Amsterdam, Netherlands). 2008;60:200\u20137.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"725_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10637-006-9023-6","volume":"25","author":"T Mikkelsen","year":"2007","unstructured":"Mikkelsen T, Lush R, Grossman SA, Carson KA, Fisher JD, Alavi JB, et al. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Investig New Drugs. 2007;25:259\u201363.","journal-title":"Investig New Drugs"},{"key":"725_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1124\/jpet.112.192849","volume":"342","author":"L Guo","year":"2012","unstructured":"Guo L, Ye C, Hao X, Zheng R, Ju R, Wu D, et al. Carboxyamidotriazole ameliorates experimental colitis by inhibition of cytokine production, nuclear factor-kappaB activation, and colonic fibrosis. J Pharmacol Exp Ther. 2012;342:356\u201365.","journal-title":"J Pharmacol Exp Ther"},{"key":"725_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1124\/jpet.107.131888","volume":"325","author":"L Guo","year":"2008","unstructured":"Guo L, Ye C, Chen W, Ye H, Zheng R, Li J, et al. Anti-inflammatory and analgesic potency of carboxyamidotriazole, a tumorostatic agent. J Pharmacol Exp Ther. 2008;325:10\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"725_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ccr.2008.04.001","volume":"13","author":"N Muller-Hermelink","year":"2008","unstructured":"Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell. 2008;13:507\u201318.","journal-title":"Cancer Cell"},{"key":"725_CR17","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","volume":"72","author":"M Platten","year":"2012","unstructured":"Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72:5435\u201340.","journal-title":"Cancer Res"},{"key":"725_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3846","volume":"14","author":"IA Murray","year":"2014","unstructured":"Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer. 2014;14:801\u201314.","journal-title":"Nat Rev Cancer"},{"key":"725_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/478192a","volume":"478","author":"GC Prendergast","year":"2011","unstructured":"Prendergast GC. Cancer: why tumours eat tryptophan. Nature. 2011;478:192\u20134.","journal-title":"Nature"},{"key":"725_CR20","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/0008-5472.CAN-06-2925","volume":"67","author":"DY Hou","year":"2007","unstructured":"Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007;67:792\u2013801.","journal-title":"Cancer Res"},{"key":"725_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/toxsci\/58.2.235","volume":"58","author":"JE Lee","year":"2000","unstructured":"Lee JE, Safe S. 3\u2032,4\u2032-dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells. Toxicol Sci. 2000;58:235\u201342.","journal-title":"Toxicol Sci"},{"key":"725_CR22","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.1242\/jcs.02663","volume":"118","author":"O Mignen","year":"2005","unstructured":"Mignen O, Brink C, Enfissi A, Nadkarni A, Shuttleworth TJ, Giovannucci DR, et al. Carboxyamidotriazole-induced inhibition of mitochondrial calcium import blocks capacitative calcium entry and cell proliferation in HEK-293 cells. J Cell Sci. 2005;118:5615\u201323.","journal-title":"J Cell Sci"},{"key":"725_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2015.10.025","volume":"370","author":"R Ju","year":"2016","unstructured":"Ju R, Guo L, Li J, Zhu L, Yu X, Chen C, et al. Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition. Cancer Lett. 2016;370:232\u201341.","journal-title":"Cancer Lett"},{"key":"725_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejphar.2006.03.036","volume":"538","author":"L Guo","year":"2006","unstructured":"Guo L, Li ZS, Wang HL, Ye CY, Zhang DC. Carboxyamido-triazole inhibits proliferation of human breast cancer cells via G(2)\/M cell cycle arrest and apoptosis. Eur J Pharmacol. 2006;538:15\u201322.","journal-title":"Eur J Pharmacol"},{"key":"725_CR25","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1073\/pnas.92.5.1307","volume":"92","author":"EC Kohn","year":"1995","unstructured":"Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA. Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci U S A. 1995;92:1307\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"725_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00210-017-1345-8","volume":"390","author":"C Chen","year":"2017","unstructured":"Chen C, Ju R, Zhu L, Li J, Chen W, Zhang DC, et al. Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-kappaB and activating SIRT1. Naunyn Schmiedeberg's Arch Pharmacol. 2017;390:423\u201333.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"725_CR27","first-page":"3208","volume":"52","author":"EC Kohn","year":"1992","unstructured":"Kohn EC, Sandeen MA, Liotta LA. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res. 1992;52:3208\u201312.","journal-title":"Cancer Res"},{"key":"725_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/jpet.117.240986","volume":"362","author":"C Chen","year":"2017","unstructured":"Chen C, Ju R, Shi J, Chen W, Sun F, Zhu L, et al. Carboxyamidotriazole synergizes with Sorafenib to combat non-small cell lung Cancer through inhibition of NANOG and aggravation of apoptosis. J Pharmacol Exp Ther. 2017;362:219\u201329.","journal-title":"J Pharmacol Exp Ther"},{"key":"725_CR29","first-page":"358","volume":"5","author":"T Wang","year":"2014","unstructured":"Wang T, Liu G, Wang R. The intercellular metabolic interplay between tumor and immune cells. Front Immunol. 2014;5:358.","journal-title":"Front Immunol"},{"key":"725_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/cmi.2017.143","volume":"15","author":"L Zhai","year":"2018","unstructured":"Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing KL, et al. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018;15:447\u201357.","journal-title":"Cell Mol Immunol"},{"key":"725_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8:539\u201351.","journal-title":"Acta Pharm Sin B"},{"key":"725_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd4596","volume":"14","author":"JL Adams","year":"2015","unstructured":"Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov. 2015;14:603\u201322.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0725-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:45:16Z","timestamp":1601041516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0725-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0725-7","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"4 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies and procedures were approved by the Institutional Animal Care and Use Committee of Peking Union Medical College (registration number: ACUC-A02\u20132017-013).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}